Namenda

PreclinicalSmall molecule

SStanford University

Namenda is one of 32 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

Cognitive DeclineCompleted

Hepatocellular CarcinomaPreclinical

Recruiting

Cognitive DeclinePreclinical

Completed

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Hepsera

Doptelet

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Valemetostat

Bristol-Myers Squibb

Preclinical

1 8

Alcohol

Astellas

Preclinical

—9

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Preclinical

3 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Hepatocellular Carcinoma

NCT06007846

Clinical

Trials by Indication[1]

Post-Operative Delirium1 trial

Namenda to Prevent Post-Operative Delirium

Terminated·UUniversity of Rochester·Phase 4·NCT00303433·30 enrolled

Cognitive Decline1 trial

Treatment With Namenda in Women at Risk for Cognitive Decline

Completed·SStanford University·N/A·NCT00242632·22 enrolled

Hepatocellular Carcinoma1 trial

A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma

Recruiting·IInova Health Care Services·Preclinical·NCT06007846·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Namenda. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Namenda compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Namenda. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

Namenda

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Post-Operative Delirium1 trial

Cognitive Decline1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News